Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Multiple System Atrophy Drugs in Development Market Overview

Multiple System Atrophy (MSA) or Shy-Drager syndrome is a neurological disorder that impairs the body’s involuntary functions (blood pressure, heart rate, bladder function, and digestion). Symptoms include rigid muscles, bradykinesia, Tremors, dysarthria, dysphagia, constipation, incontinence, and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson medications.

The Multiple System Atrophy pipeline drugs market research report provides comprehensive information on the therapeutics under development for MSA and analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Multiple System Atrophy and features dormant and discontinued projects.

Multiple System Atrophy Pipeline Drugs Market Segmentation by Targets

Some of the targets of the Multiple System Atrophy pipeline drugs market are Alpha Synuclein, Myeloperoxidase, Alkaline Phosphatase, Amine Oxidase [Flavin Containing] B, Calcium Channel, Cardiolipin, Coenzyme Q10, FAS Associated Factor 1, Glial Cell Line Derived Neurotrophic Factor , Glutamate Ionotropic Receptor NMDA Type Subunit, Insulin Like Growth Factor 1 Receptor, Major Prion Protein, NACHT LRR And PYD Domains Containing Protein 3, Sodium Channel, Toll Like Receptor 2, Transcription Factor EB, and Tyrosine Protein Kinase ABL. In 2022, Alpha Synuclein led this segment of the Multiple System Atrophy pipeline drugs market.

Multiple System Atrophy Pipeline Drugs Market Analysis by Targets, 2022 (%)

 For more Multiple System Atrophy pipeline drugs market target insights, download a free report sample

Multiple System Atrophy Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the key mechanisms of action of the Multiple System Atrophy pipeline drugs market are Alpha Synuclein Inhibitor, Myeloperoxidase Inhibitor, Alkaline Phosphatase Inhibitor, Amine Oxidase [Flavin Containing] B Inhibitor, Calcium Channel Blocker, FAS Associated Factor 1 Inhibitor, and Glial Cell Line Derived Neurotrophic Factor Activator among others. Alpha Synuclein Inhibitor led the Multiple System Atrophy pipeline drugs market in terms of MoA in 2022.

Multiple System Atrophy Pipeline Drugs Market Analysis by Mechanisms of Action, 2022 (%)

 For more mechanisms of action insights into the Multiple System Atrophy pipeline drugs market, download a free report sample

Multiple System Atrophy Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Multiple System Atrophy pipeline drugs market are oral, intravenous, intrathecal, subcutaneous, intraarterial, and parenteral. The most adopted RoA for the Multiple System Atrophy Pipeline drugs market was oral in 2022.

Multiple System Atrophy Pipeline Drugs Market Analysis, by Routes of Administration, 2022 (%)

For more routes of administration insights into the Multiple System Atrophy pipeline drugs market, download a free report sample

Multiple System Atrophy Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Multiple System Atrophy pipeline drugs market are Small Molecule, Monoclonal Antibody, Gene Therapy, Cell Therapy, Antibody, Antisense Oligonucleotide, Conjugate Vaccine, and Subunit Vaccine. Small Molecule accounted for the largest Multiple System Atrophy pipeline drugs market share in terms of molecule types.

Multiple System Atrophy Pipeline Drugs Market Analysis by Molecule Types, 2022 (%)

For more molecule type insights into the Multiple System Atrophy pipeline drugs market, download a free report sample

Multiple System Atrophy Pipeline Drugs Market - Competitive Landscape

Some of the key companies in the Multiple System Atrophy pipeline drugs market are Teva Pharmaceutical Industries Ltd, AC Immune SA, Alterity Therapeutics Ltd, Biohaven Pharmaceutical Holding Company Ltd, Coave Therapeutics, Corestem Inc, Neuramedy Co Ltd, and others. In 2022, Teva Pharmaceutical Industries Ltd. had the highest number of products under development.

Multiple System Atrophy Pipeline Drugs Market Analysis by Companies, 2022 (%)

To know more about the Multiple System Atrophy pipeline drugs companies, download a free report sample

Segments Covered in this Report

Multiple System Atrophy Pipeline Drugs Target Outlook (Number of Pipeline Drugs, 2022)

• Alpha Synuclein
• Myeloperoxidase
• Alkaline Phosphatase
• Amine Oxidase [Flavin Containing] B
• Calcium Channel
• Others

Multiple System Atrophy Pipeline Drugs MoA Outlook (Number of Pipeline Drugs, 2022)

• Alpha Synuclein Inhibitor
• Myeloperoxidase Inhibitor
• Alkaline Phosphatase Inhibitor
• Amine Oxidase [Flavin Containing] B Inhibitor
• Others

Multiple System Atrophy Pipeline Drugs RoA Outlook (Number of Pipeline Drugs, 2022)

• Oral
• Intravenous
• Intrathecal
• Subcutaneous
• Others

Multiple System Atrophy Pipeline Drugs Molecule Types Outlook (Number of Pipeline Drugs, 2022)

• Small Molecule
• Monoclonal Antibody
• Gene Therapy
• Cell Therapy

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple System Atrophy.
• The pipeline guide reviews pipeline therapeutics for Multiple System Atrophy by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Multiple System Atrophy therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Multiple System Atrophy therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for Multiple System Atrophy

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Multiple System Atrophy.
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding the Multiple System Atrophy pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.